MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.82 -0.26

Resumen

Variación precio

24h

Actual

Mínimo

3.8

Máximo

3.98

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+13.33% upside

Dividendos

By Dow Jones

Próximas Ganancias

17 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

360M

1.4B

Apertura anterior

4.08

Cierre anterior

3.82

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ene 2026, 21:55 UTC

Ganancias

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 ene 2026, 23:52 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 ene 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 ene 2026, 23:40 UTC

Charlas de Mercado

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 ene 2026, 22:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 ene 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

22 ene 2026, 21:44 UTC

Ganancias

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 ene 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 ene 2026, 21:30 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One To Acquire Brex >COF

22 ene 2026, 21:13 UTC

Ganancias

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 ene 2026, 21:10 UTC

Ganancias

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 ene 2026, 21:06 UTC

Ganancias

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Rev $15.58B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q EPS $3.26 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Interest Margin 8.26% >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net $2.13B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Adj EPS $3.86 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Charge-Offs $3.8B >COF

22 ene 2026, 21:05 UTC

Ganancias

Intuitive Surgical 4Q EPS $2.21 >ISRG

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

13.33% repunte

Estimación a 12 meses

Media 4.25 USD  13.33%

Máximo 4.5 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat